Arcadia Biosciences, Inc. (RKDA)
NASDAQ: RKDA · Real-Time Price · USD
1.070
+0.010 (0.94%)
At close: Apr 24, 2026, 4:00 PM EDT
1.100
+0.030 (2.80%)
After-hours: Apr 24, 2026, 4:00 PM EDT
← View all transcripts

Earnings Call: Q3 2022

Nov 10, 2022

Operator

Good afternoon, and welcome to the Arcadia Biosciences third quarter 2022 earnings conference call. Today's presenters will be Stan Jacot, President and Chief Executive Officer, and Pam Haley, Chief Financial Officer of Arcadia. This call is being webcast, and you can refer to the company's press release at the arcadiabio.com. Before we start, we would like to remind you that Arcadia Biosciences will be making forward-looking statements on this call based on current expectations and currently available information. However, since these statements are based on factors that involve risks and uncertainties, the company's actual performance and results may differ materially from those described or implied today. You can review the company's safe harbor language in their most recently filed 10-Q. If you'd like to ask a question during the presentation, please press zero one on your touchtone phone.

With that, I will now turn the call over to Stan Jacot, CEO. Sir, you may begin.

Stan Jacot
President and CEO, Arcadia Biosciences

Good afternoon, and thank you for joining us today for our 2022 third quarter conference call. Our third quarter results represent continued progress on our path to profitability that we've discussed on previous earnings calls as part of our long-term strategy called Project Greenfield. As noted in our press release, key highlights include, 1, our distribution for GoodWheat doubled from the previous quarter, and 2, our gross margins improved to 28%, validation that we are on the right track. Our Q3 revenues reflect the transformation to a leaner, more focused company. We have divested unprofitable lines of business, and Q3 has not included any non-recurring revenues from grain sales or the Bioceres HB4 soybean milestone that we reported in Q1 and Q2. This is all part of our business plan, and it is working.

While our Q3 revenues were below Q1 and Q2, our Q3 gross profit dollars were higher than the first two quarters combined. I am extremely pleased with the quality of our third quarter revenues, our improvement in gross margins, and the distribution gains we have made on GoodWheat in a very short period of time, which is a perfect transition to the first topic I wanted to discuss with you today, the success we are having with GoodWheat. On our Q1 earnings call in mid-May, we announced that GoodWheat pasta had officially launched in the retail channel in May 2022. On our Q2 earnings call in mid-August, we communicated that we added the e-commerce channel with our launch on Amazon, and we discussed that we added more and more retailers at a rapid pace as interest grew around our great-tasting, better-for-you pasta.

At that time, GoodWheat pasta was available in nearly 500 stores, significant progress for a brand that launched just two months earlier. We also projected that store count would double by the end of the year. Today, I'm excited to report that our distribution has already doubled in the third quarter alone, with GoodWheat pasta now available nationwide in nearly 1,000 retail stores. This is an amazing accomplishment for the GoodWheat brand and Arcadia as a whole, so I would like to take a minute and thank the team for all of their hard work and collaboration in making this launch a success. It was truly a cross-functional team effort, and we are extremely proud that the launch is exceeding our own internal expectations. Beyond the launch in new stores, we are committed to supporting our retail customers and driving trial of GoodWheat where we already have placement.

There are a variety of programs that we are utilizing to drive awareness and traffic to our partners, including price promotions, coupons, displays, ads, social media, and influencers. Needless to say, I am delighted with the progress we have made and the feedback we have received from our partners regarding the differentiated value proposition GoodWheat is bringing to the pasta aisle. I'm also encouraged by how the pasta category has performed. Based on category data from Nielsen for the 13 weeks ending September 24th, which essentially covers our third quarter, pasta category sales grew 25% compared to the same period last year, and units were up 2.4%. We believe the pasta category will continue to be a bright spot in the face of rising food costs in a tough economic environment, so we feel very good about the future prospects for GoodWheat.

As we've discussed before, pasta is just one of many categories where we believe our proprietary superior wheat can add value. I will touch more on this later, but let me shift now to our other core brands, Zola coconut water and ProVault Pain Relief. The coconut water category continues to grow, primarily driven by price increases. In the 13 weeks ending September twenty-fourth, category sales increased 9.7%, while units declined 6%, which was an improvement from the previous quarter when units declined 15%. Zola continues to perform well and is one of only a handful of brands in the category that is growing both dollar sales and unit sales. Dollar sales increased 8%, and unit sales grew 4% compared to the same period last year.

As we mentioned last quarter, we see opportunity for Zola to increase distribution as consumers prefer the taste of Zola to other leading coconut water brands in a blind, unbranded taste test. As a result, we are refreshing our packaging, working on new innovation, and are taking our message to retailers in order to gain new shelf space. Moving to ProVault, the topical pain relief category sales declined 3.8%, and units fell 9.9% in the 13 weeks ending September 24th. The CBD market has been hit especially hard in the current economic environment as a result of higher price points, and we have seen some retailers step completely out of CBD products. Despite this tougher than expected landscape, ProVault distribution increased 6% and sales grew 51% compared to the same period last year.

Now, I want to shift gears and provide an update on our exit from certain business lines. As we've previously discussed, Arcadia has been focused on simplifying its operations and placing an intense focus on businesses that, one, have a large opportunity and a differentiated product. Two, the ability to easily scale the business without significant capital. Three, meets our profitability goals. In Q1, we announced we would wind down our legacy co-packing business that we inherited as a part of our 2021 acquisition. In Q2, we reported that this was complete. We also communicated in Q2 that we would divest our manufacturing facility as well as the Savvy Naturals brand, and I'm happy to report that those transitions were completed on August first. These changes simplified our business, freed up cash, and allowed us to focus on higher margin SKUs.

This focus resulted in higher quality revenue and a nearly 1,800 basis points improvement in gross margins. This level of improvement is significant, so I think it is important to spend a few minutes to talk about the deliberate financial progress made at Arcadia over the first nine months of 2022 compared to the first nine months of 2021. Our revenues of approximately $9 million are up $4.3 million or 94% compared to the same period last year. While 2021 does not include a full nine months of acquisition revenue, if we remove those sales completely from both years, our revenues have still increased 40%. During the same time frame, our gross profit has increased more than $1 million, leading to a 1,500 basis points improvement in our gross margin through the first nine months.

This is a testament to the decisions we have made to unwind underperforming businesses and focus on profitable growth. At the same time, our total operating expenses, including cost of goods sold of $21.9 million, has decreased $4.4 million or 17%, which validates our ability to grow the business while keeping our costs under control. Our reported loss from operations for the first nine months of approximately $13 million improved by $8.7 million or 40% compared to last year. Finally, our use of cash from operations improved by $7.9 million or 41% during the first nine months of 2022 compared to the same period last year.

While there's a lot of work still to do, we have made tremendous progress simplifying our business and focusing on the most profitable brands while doing a better job of managing our cash. Speaking of cash, we ended the third quarter with $22.7 million in cash and cash equivalents, bolstered by the $5 million of gross proceeds from the registered direct offerings in August. We believe this is sufficient to fund our operations through 2023. Currently, we are in the exploratory phase of evaluating potential acquisition targets that would allow us to bring the GoodWheat value proposition to an existing brand in the new wheat-based category outside of pasta. As I briefly mentioned earlier in my comments, pasta is just one of many categories in the grocery aisle where our wheat can provide significant differentiation.

We believe there is a tremendous opportunity to scale our business faster by purchasing an existing branded in a different category that already has broad shelf placement and established distribution. This initiative is a component of Project Greenfield, which we laid out in prior quarters. As a reminder, the first strategy in Project Greenfield was to establish GoodWheat footholds in categories representing over $10 billion in annual consumer spending. Furthermore, we indicated that that strategy could include a mix of product launches as well as potential acquisitions. To execute this initiative, we may access the capital markets earlier than planned in anticipation of using those funds for acquisition purposes and increasing sales and marketing investments for further GoodWheat expansion.

We are in the very, very early stages, so more to come, but I wanted to share with you our current thinking, and I will keep you updated if there is any news to share on this front. This concludes my prepared remarks. With that, I will now turn the call over to Pam to discuss our 2022 Q3 financial results in more detail. Pam?

Pam Haley
CFO, Arcadia Biosciences

Thanks, Stan. Good afternoon, everyone. As Stan noted, we had anticipated reduced revenue in third quarter as we have turned our focus on our higher margin brands. Total revenues recognized for third quarter 2022 were $1.9 million compared to $2.4 million in the third quarter of 2021 for a decrease of 21%, but resulting in a positive growth margin of 28%. As mentioned earlier, third quarter year-to-date revenues were $4.3 million higher than third quarter year-to-date 2021 for an increase of 94%. The year-to-date growth margin was 8%, impacted by the first half sales of underperforming businesses, which we have since divested. Lower revenues from co-packing and Savvy Naturals product sales accounted for the majority of the decrease for the quarter.

Partially offsetting this unfavorability was the GoodWheat pasta revenue recognized this quarter. As previously communicated, we launched our GoodWheat pasta at the end of second quarter this year and are very pleased with the progress to date. The $4.3 million favorability in year-to-date revenues for 2022 as compared to 2021 was driven by a full nine months of coconut water and body care product sales, in addition to the GoodWheat pasta and grain sales this year.

Total operating expenses of $6.5 million in third quarter of 2022 was $4.6 million less than the $11.1 million recognized in the third quarter of 2021, and third quarter year-to-date total operating expenses was $4.4 million lower than the same period in 2021. As Stan mentioned, we have been focused on cost containment, which is reflected in our results here. Cost of product revenues was lower for the quarter, in line with the lower revenues recognized. SG&A expenses were $1.2 million favorable for the quarter due to the impairment of property and equipment that was recognized in third quarter 2021, with an immaterial amount recognized in third quarter 2022.

Also impacting the total operating expense favorability this quarter was the $1.5 million lower SG&A expense recognized in 2022 as compared to 2021, primarily driven by reduced employee, lease, and consulting expenses. Cost of product revenues for the first nine months of 2022 was $8.3 million, or $3.3 million higher than the $5 million in the first nine months of 2021, the result of higher revenues recognized during the same period. The other components of total operating expenses were all lower during the first nine months of 2022. SG&A was $2.9 million lower, driven by the lower employee, lease, and consulting expenses, along with the absence of acquisition fees recognized in 2021. R&D was $2.3 million lower as the company's focus has turned to commercialization this year.

As discussed on the second quarter call, a gain on the sale of Verdeca in the amount of $1.1 million was recognized in the second quarter of 2022, with a $2 million milestone fee from Bioceres triggered by the Chinese approval of HB4 soy. Net loss attributable to common stockholders was $2.9 million in third quarter 2022 versus $2.2 million in third quarter of 2021. Loss from operations was $4.1 million lower, as we just reviewed, and offsetting this favorability was $2.9 million greater non-cash income from the change in fair value of common stock warrant and option liabilities in third quarter 2021 compared to third quarter 2022, along with the $1.1 million gain on extinguishment of the PPP loan in third quarter of 2021.

We are back to remeasuring the change in fair value of common stock warrant and option liabilities with the preferred investment options issued in the August registered direct offering. Net loss attributable to common stockholders in the first nine months of 2022 was $11.1 million versus $5.4 million for the same period in 2021, a difference of $5.7 million. Loss from operations was $8.7 million lower third quarter 2022 year-to-date versus 2021 year-to-date, but 2021 included a $10.2 million gain from the sale of Bioceres shares that was not present in 2022. This concludes our financial highlights for the third quarter and first nine months of 2022. Thank you very much for your time and attention, and I'll turn the call over to the operator for questions. Operator?

Operator

Thank you. We will now begin the question and answer session. If you'd like to ask a question, please press zero one on your touch-tone phone. If you are using a speakerphone, you need to pick up your handset first before pressing any numbers. Once again, if you'd like to ask a question, please press zero one on your touch-tone phone. Our first question comes from Ben Klieve from Lake Street Capital Markets. Your line is now open.

Ben Klieve
Senior Research Analyst, Lake Street Capital Markets

All right. Thanks for taking my questions here this afternoon. First question on growth margins. Great progress there in the quarter. You know, with this now, you know, really streamlined business that you have with, you know, three kind of primary product categories and the first quarter of material gross profit, can you talk about kind of the margin characteristics across each of those three product categories? Because I'm curious if they're kind of relatively in line with each other or if individual products that really drive this number right now.

Pam Haley
CFO, Arcadia Biosciences

Thank you for the question, Ben. We're at this point for our three product lines, you know, all of the different individual SKUs are a little different. We would say that our line of sight to growth would keep us in the same gross margin range as we experienced in Q3.

Ben Klieve
Senior Research Analyst, Lake Street Capital Markets

Okay. Thank you. A couple questions on GoodWheat specifically. First, regarding retail distribution, I mean, you know, great progress there, you know, expanding store count as quickly as you did. You know, I'm wondering now, you know, what comes next. Can you help us kind of frame realistic expectations for retail count progressing over the next few quarters, say through the end of 2023 or some kind of timeframe in that range?

Stan Jacot
President and CEO, Arcadia Biosciences

Again, we continue to present GoodWheat to many retailers across the nation. Depending on shelf reset timeframes, which will last all the way through this time in 2023, you know, we would expect to get to the 3,000-5,000 distribution points by the end of 2023.

Ben Klieve
Senior Research Analyst, Lake Street Capital Markets

Okay. Perfect. Thank you, Stan. You're loud and clear on the opportunity to integrate GoodWheat into, you know, other categories, potentially via acquisition. I'm wondering if you can also elaborate on your kind of expectation on expanding the addressable market beyond CPG, you know, that you control, you know, via, you know, B2B revenues via the ongoing trial underway with Bioceres in South America. You know, is there any kind of updates you can provide on either of those fronts?

Stan Jacot
President and CEO, Arcadia Biosciences

Yeah. We still continue to look for partnerships and continue to leverage the partnerships we currently have with companies like Bioceres. There's nothing really new to report for this year.

At this point, nothing new in the pipeline that will significantly impact our projections.

Ben Klieve
Senior Research Analyst, Lake Street Capital Markets

Okay. All right. Very good. You know, one last one for me. You know, with all the, you know, kind of moving pieces here recently with, you know, exiting businesses and exiting the, you know, your processing facilities, are there any kind of, you know, cash inflows, outflows here expected here from, you know, in Q4 and beyond, around this broad initiative of streamlining your operations, or have those all really been realized, you know, as of Q3?

Stan Jacot
President and CEO, Arcadia Biosciences

Yeah, Ben, I'll turn that over to Pam to answer.

Pam Haley
CFO, Arcadia Biosciences

Hi, Ben. I don't think that we don't expect a lot from the cash perspective. I mean, we still will be evaluating, you know, as we do each quarter, and especially at the end of the year, the inventory balances and the asset balances we have at the end of the year. We will be, you know, looking at those to right-size them to fair market value. There could be, you know, some additional write-downs, but we really don't expect much in the way of cash going out.

Ben Klieve
Senior Research Analyst, Lake Street Capital Markets

Okay. All right. That makes sense. All right, well, I think I'm in good shape. Congratulations again on some really good progress on several fronts, and I'll get back in queue.

Pam Haley
CFO, Arcadia Biosciences

Thank you.

Operator

Thank you. Our next question comes from Deepesh Patel from H.C. Wainwright. Your line is now open.

Deepesh Patel
Equity Research Associate, H.C. Wainwright & Co.

Hi, guys. Thanks for the update. Just standing in for Ram Selvaraju at H.C. Wainwright & Co. When do you plan to reach operating cash flow breakeven?

Stan Jacot
President and CEO, Arcadia Biosciences

As a part of Project Greenfield, we expect that to happen in early 2025.

Deepesh Patel
Equity Research Associate, H.C. Wainwright & Co.

Okay. With regards to some of your products, do you expect to receive any consideration for whatever remaining hemp-related inventory you are still holding? And if so, what might that look like?

Stan Jacot
President and CEO, Arcadia Biosciences

With that, I'll turn that one over to Pam.

Pam Haley
CFO, Arcadia Biosciences

Sure. We, you know, the CBD market has been pretty challenged lately, and we are still looking to to monetize the hemp assets that we have on our books. I mean, it's a continuous evaluation and, depending on how that market outlook truly does look for next year, we'll just have to see. But it's pretty challenging right now.

Deepesh Patel
Equity Research Associate, H.C. Wainwright & Co.

Okay. Last question. How would you characterize the level of commitment among distributors for your GoodWheat product line, and what strategies are they employing in order to drive that uptake?

Stan Jacot
President and CEO, Arcadia Biosciences

Yeah. Our partners that we've listed GoodWheat are very satisfied with our performance. I would say for most of them, we are very early on in the trial-driving period. As you know, once we secure distribution, we have to get in queue for promotions and which include feature ads, include display. We are just now starting to see some of those promotion activities hit the marketplace. And with that, we see the corresponding lift and corresponding trial. But yes, the acceptance has been strong. Commitment to our brand has been strong and, you know, as we mentioned in the remarks, we're looking at all the typical promotion tools and marketing tools to continue to improve our velocities.

Deepesh Patel
Equity Research Associate, H.C. Wainwright & Co.

Great. Thank you, Stan and Pam.

Pam Haley
CFO, Arcadia Biosciences

Thank you.

Operator

Presenters, I show no further questions in queue at this time. I will turn the call back to Mr. Stan Jacot for closing comments.

Stan Jacot
President and CEO, Arcadia Biosciences

Thank you. So in closing, we have made meaningful progress this year in transitioning Arcadia to a more lean and focused organization. Our financial results continue to improve as evidenced by our significant increase in gross profit in Q3, as well as our ongoing management of expenses. GoodWheat continues to outperform expectations with distribution doubling in the third quarter alone. We believe that our numbers validate our ability to execute on the long-term plans we have previously shared and look forward to sharing with you our full year results on our next call. Thank you again for joining us today. Have a great afternoon, everyone.

Operator

Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect.

Powered by